Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Capital Employed (2021 - 2025)

Gain Therapeutics (GANX) has 5 years of Return on Capital Employed data on record, last reported at 2.82% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 106.0% year-over-year to 2.82%; the TTM value through Sep 2025 reached 2.82%, down 106.0%, while the annual FY2024 figure was 1.78%, 42.0% down from the prior year.
  • Return on Capital Employed reached 2.82% in Q3 2025 per GANX's latest filing, up from 3.12% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.19% in Q2 2021 and bottomed at 3.12% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 1.42%, with a median of 1.57% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: crashed -151bps in 2023, then soared 39bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.36% in 2021, then tumbled by -122bps to 0.8% in 2022, then crashed by -142bps to 1.95% in 2023, then decreased by -12bps to 2.18% in 2024, then fell by -29bps to 2.82% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 2.82% in Q3 2025, 3.12% in Q2 2025, and 2.97% in Q1 2025.